1. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
- Author
-
David R. Jones, Shanu Modi, Alain Vincent, William D. Travis, Marjorie G. Zauderer, Prasad S. Adusumilli, Valerie W. Rusch, Bobby Daly, Brigitte Senechal, Devanjan S. Sikder, Daniel Ngai, Jennifer L. Sauter, Waseem Cheema, Michel Sadelain, Rocio Perez-Johnston, Claudia Diamonte, Renier J. Brentjens, Jose A. Araujo Filho, Stephen B. Solomon, Amy Zhu, Elizabeth Halton, John Pineda, Xiuyan Wang, Roisin E. O'Cearbhaill, Navin K. Chintala, Kay See Tan, Erin McGee, Charles M. Rudin, Mithat Gonen, and Isabelle Riviere
- Subjects
Oncology ,medicine.medical_specialty ,Lung ,biology ,business.industry ,Anti pd 1 ,Pembrolizumab ,medicine.disease ,Chimeric antigen receptor ,Blockade ,Pleural disease ,medicine.anatomical_structure ,Internal medicine ,medicine ,biology.protein ,Mesothelin ,In patient ,business - Abstract
Malignant pleural diseases, comprising metastatic lung and breast cancers and malignant pleural mesothelioma (MPM), are aggressive solid tumors with poor therapeutic response. We developed and conducted a first-in-human, phase I study of regionally delivered, autologous, mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy. Intrapleural administration of 0.3M to 60M CAR T cells/kg in 27 patients (25 with MPM) was safe and well tolerated. CAR T cells were detected in peripheral blood for >100 days in 39% of patients. Following our demonstration that PD-1 blockade enhances CAR T-cell function in mice, 18 patients with MPM also received pembrolizumab safely. Among those patients, median overall survival from CAR T-cell infusion was 23.9 months (1-year overall survival, 83%). Stable disease was sustained for ≥6 months in 8 patients; 2 exhibited complete metabolic response on PET scan. Combination immunotherapy with CAR T cells and PD-1 blockade agents should be further evaluated in patients with solid tumors. Significance: Regional delivery of mesothelin-targeted CAR T-cell therapy followed by pembrolizumab administration is feasible, safe, and demonstrates evidence of antitumor efficacy in patients with malignant pleural diseases. Our data support the investigation of combination immunotherapy with CAR T cells and PD-1 blockade agents in solid tumors. See related commentary by Aldea et al., p. 2674. This article is highlighted in the In This Issue feature, p. 2659
- Published
- 2021
- Full Text
- View/download PDF